Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

No antithrombotic therapy after TAVR? New research highlights potential benefits

The study, published in JACC: Cardiovascular Interventions, focused on data from more than 3,500 TAVR patients. 

Minima Stent Cedars Sinai adjustable children cardiology

Cardiologists explore the real-world potential of new adjustable stents for children

The new-look adjustable stents, not yet fully approved by the FDA, can be expanded as a child ages. The hope is that these stents will never need to be replaced.

Gabler Survivor Heart Valve Specialist TAVR

Mike Gabler, a heart valve specialist with Edwards Lifesciences, wins Survivor—and donates his $1M prize

Gabler, a Texas native, has two decades of experience in the cardiology space, spending the last 11 years with Edwards Lifesciences. He has also previously worked for both Medtronic and Boston Scientific.

An updated look at the latest self-expandable and balloon-expandable TAVR devices

Researchers have completed a new analysis of the Evolut Pro and Pro+ devices from Medtronic and the Sapien 3 Ultra devices from Edwards Lifesciences, sharing the results in JACC: Cardiovascular Interventions.

Most devices implanted during LAAO procedures are oversized—and patients benefit

Oversized devices are becoming more common as time goes on, which suggests operators are growing increasingly comfortable with this treatment choice.

Boston Scientific Acurate neo2 TAVR

Boston Scientific's new TAVR system associated with high success rate, low mortality rate

The new-look device gained CE mark approval in Europe in 2020, but it has not been approved yet in the United States.

Thumbnail

Socioeconomic status and mental health make a big impact on AVR outcomes

Nontraditional risk factors such as dementia, PTSD, bipolar disorder and low socioeconomic status are all important to consider when patients are candidates for aortic valve replacement. 

Anteris Technologies duravr heart valve

Regulatory Roundup: Updates on Medtronic and LivaNova recalls, FDA-cleared AI models, a new heart valve and more

Read our recap of some of the biggest FDA-related stories that impacted cardiology in the last month.

Displaying 353 - 360 of 876
Design by Adaptive Theme